Search Results - "Gouttefangeas, C"

Response definition criteria for ELISPOT assays revisited by Moodie, Z, Price, L, Gouttefangeas, C, Mander, A, Janetzki, S, Löwer, M, Welters, M. J. P, Ottensmeier, C, van der Burg, S. H, Britten, Cedrik M

“…No consensus has been reached on how to determine if an immune response has been detected based on raw data from an ELISPOT assay. The goal of this paper is to…”
Get full text

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact by Britten, C.M., Janetzki, S., Butterfield, L.H., Ferrari, G., Gouttefangeas, C., Huber, C., Kalos, M., Levitsky, H.I., Maecker, H.T., Melief, C.J.M., O’Donnell-Tormey, J., Odunsi, K., Old, L.J., Ottenhoff, T.H.M., Ottensmeier, C., Pawelec, G., Roederer, M., Roep, B.O., Romero, P., van der Burg, S.H., Walter, S., Hoos, A., Davis, M.M.

“…[...]the current version of MIATA is a testimonial to the freedom and transparency of research and proves the ability of the research community to form…”
Get full text

Abstract # 1730 Cytotoxic T cells of different antigen specificity are differentially regulated by the circadian system in humans by Besedovsky, L, Dimitrov, S, Gouttefangeas, C, Born, J, Rammensee, H, Lange, T

“…In humans, the numbers of cytotoxic T lymphocytes (CTLs) in blood display a strong circadian rhythm with a steep decrease from night to daytime. However, CTLs…”
Get full text

Abstract # 1813 G-alpha-s-protein coupled receptor signaling suppresses integrin-mediated cell adhesion of antigen-specific human CD8+ T cells by Dimitrov, S, Besedovsky, L, Jensen, A.T, Born, J, Gouttefangeas, C, Rammensee, H, Lange, T

“…An efficient immune response requires a selective and strong interaction of T cells with endothelium or target cells. These interactions are strengthened by…”
Get full text

Toward the harmonization of immune monitoring in clinical trials: Quo vadis? by Britten, C. M., Janetzki, S., van der Burg, S. H., Gouttefangeas, C., Hoos, A.

Get full text

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays by Britten, C. M., Gouttefangeas, C., Welters, M. J. P., Pawelec, G., Koch, S., Ottensmeier, C., Mander, A., Walter, S., Paschen, A., Müller-Berghaus, J., Haas, I., Mackensen, A., Køllgaard, T., thor Straten, P., Schmitt, M., Giannopoulos, K., Maier, R., Veelken, H., Bertinetti, C., Konur, A., Huber, C., Stevanović, S., Wölfel, T., van der Burg, S. H.

“…The interpretation of the results obtained from immunomonitoring of clinical trials is a difficult task due to the variety of methods and protocols available…”
Get full text

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells by Janetzki, Sylvia, Price, L, Britten, C. M, van der Burg, S. H, Caterini, J, Currier, J. R, Ferrari, G, Gouttefangeas, C, Hayes, P, Kaempgen, E, Lennerz, V, Nihlmark, K, Souza, V, Hoos, A

“…The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance,…”
Get full text

Immunosenescence, suppression and tumour progression by PAWELEC, G, KOCH, S, GRIESEMANN, H, REHBEIN, A, HÄHNEL, K, GOUTTEFANGEAS, C

“…There are good arguments for suggesting that two seminal papers published 50 years ago can be taken as the beginning of modern tumour immunology. These papers…”
Get full text

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program by Mander, A, Gouttefangeas, C, Ottensmeier, C, Welters, M. J. P, Low, L, van der Burg, S. H, Britten, C. M

“…The Cancer Immunotherapy Immunoguiding Program has conducted an IFN-γ ELISPOT proficiency panel to examine the influence of serum supplementation of test media…”
Get full text

CIMT meets Strategies for Immune Therapy: Mainz, Germany, 04–05 May 2006 by Gouttefangeas, C., Britten, C. M., Badalians, E. Derhovanessian, Pawelec, G.

Get full text

Cancer immunotherapy 2005: Mainz, Germany, 12-13 May 2005 by Britten, C M, Gouttefangeas, C, Kreiter, S

“…Cancer Immunotherapy 2005 was the third international meeting organized by the Association for Immunotherapy of Cancer (AIC). About 200 participants were…”
Get full text

Strategies for immune therapy: Würzburg, Germany, 29 February-3 March 2004 by Pawelec, G, Gouttefangeas, C

Get full text

High frequency of human cytomegalovirus (HCMV)-specific CD8+ T cells detected in a healthy CMV-seropositive donor by Lang, K S, Moris, A, Gouttefangeas, C, Walter, S, Teichgräber, V, Miller, M, Wernet, D, Hamprecht, K, Rammensee, H G, Stevanovic, S

“…Human cytomegalovirus (HCMV) persists after infection but is controlled by cellular immune responses, particularly by CD8+ T cells. If infected individuals are…”
Get full text

Functional T lymphocytes infiltrate implanted polyvinyl alcohol foams during surgical wound closure therapy by Gouttefangeas, C., Eberle, M., Ruck, P., Stark, M., Müller, J. E., Becker, H‐D., Rammensee, H‐G., Pinocy, J.

“…Vacuum‐assisted closure involving the implantation of polyvinyl alcohol foam is a technique recently developed for the treatment of patients suffering from…”
Get full text

PO-1292: Radiation planning parameters correlate with peripheral immune status during prostate radiotherapy by Eckert, F., Frey, B., Zips, D., Gani, C., Rammensee, H., Gouttefangeas, C.

Get full text

Problem solving for tumor immunotherapy by Gouttefangeas, Cécile, Rammensee, Hans-Georg

“…Tumor cells express defined antigens that can be recognized by tumor-destroying (CD8 super(+)) cytotoxic T lymphocytes (CTLs). As most cancer patients…”
Get full text

Expression of checkpoint receptors in tumor-infiltrated T-cells of renal cell and prostate carcinomas by Bedke, J, Zelba, H, Hennenlotter, J, Zettl, M, Rammensee, H.-G, Stenzl, A, Gouttefangeas, C

Get full text

Abstract # 3233 Sleep supports integrin activation on antigen-specific T cells via suppression of Gαs-coupled receptor signaling by Besedovsky, L., Lange, T., Gouttefangeas, C., Jensen, A.T., Szczepanski, M., Lehnholz, J., Soekadar, S., Rammensee, H., Born, J., Dimitrov, S.

Get full text

303P EO2401 (EO) therapeutic vaccine for patients (pts) with recurrent glioblastoma (GB): Phase I/II ROSALIE study by Reardon, D.A., Idbaih, A., Vieito Villar, M., Tabatabai, G., Stradella, A., Ghiringhelli, F., Burger, M., Gonzalez Rodriguez, M., Hervieu, A., Mildenberger, I., Gil Martín, M., Renovanz, M., Touat, M., Wen, P., Wick, A., Gouttefangeas, C., Maia, A., Bonny, C., Fagerberg, J., Wick, W.

Get full text

Managing Multi-center Flow Cytometry Data for Immune Monitoring by White, Scott, Laske, Karoline, Welters, Marij J.P., Bidmon, Nicole, Van Der Burg, Sjoerd H., Britten, Cedrik M., Enzor, Jennifer, Staats, Janet, Weinhold, Kent J., Gouttefangeas, Cέcile, Chan, Cliburn

“…With the recent results of promising cancer vaccines and immunotherapy1–5, immune monitoring has become increasingly relevant for measuring treatment-induced…”
Get full text